SGLT2 inhibitors curb the action of a protein known as sodium-glucose cotransporter 2, which helps the kidneys reabsorb glucose from the blood.

A network meta-analysis explored the effects of a combination of SGLT2 inhibitor and MRA on albuminuria and blood pressure in patients with type 2 diabetes.

Ultimately, Sourij said the "holy grail" would be to understand how SGLT2 inhibitors really work, as different mechanisms have been proposed.

Adding a glucagon receptor antagonist to SGLT2 inhibitor therapy improved glycemic control, reduced insulin use, and appeared to mitigate risk of diabetic ketoacidosis in patients with T1D.

During her presentation, she added that these findings warrant additional study of SGLT2 inhibitors in patients with rheumatic disease, to provide a cost-benefit analysis of SGLT2-inhibitor use.

SGLT2 inhibitor increases insulin sensitivity of the brain "While placebo administration had no influence on insulin action in the brain, empagliflozin treatment significantly improved the effect ...

BOLD MRI can measure kidney oxygenation non-invasively, and this is expected to become an important technology for elucidating the mechanisms of kidney disease for the development of therapeutic ...

SGLT2 inhibitor therapy in patients with heart failure is associated with a significantly lower incidence of sudden cardiac death vs. placebo, with the benefit persisting independent of other ...

The first poster, “ Sotagliflozin, a Dual SGLT1/2 Inhibitor, Reduced Expression of Neutrophil Degranulation Proteins During Endothelial Dysfunction Compared with a Selective SGLT2 Inhibitor ...